Daily One Unpopular US Stock:

$ANAB

【Personal Opinion】: A game-like Royalty-based small-cap biotech; suitable for a light position ahead of FDA catalysts. Not recommended for a heavy allocation for long-term holding.

Core Data:

Current price: about $65.43 | Total market cap: about $1.937 billion

Q1 collaboration revenue: $25.56 million | Cash and investments on the books: $286.5 million

30-day average daily trading volume: about $5.12 million | Short interest coverage: about 8 days

My reasoning logic:

1、The company has completed its business split, and its core value has shifted toward royalty cash flow. Currently, its main revenue comes from GSK Jemperli royalties and Vanda imsidolimab licensing collaborations. As Jemperli continues to ramp up, the company’s future cash flow has some growth potential. Meanwhile, it has already launched a $100 million stock repurchase plan, which provides some support for the stock price.

2、The key catalyst comes from imsidolimab.

Potential Risks:

① The company still has approximately $264 million in royalty financing liabilities; in the future, part of the Jemperli royalty cash flow will need to be prioritized to repay the Sagard financing arrangement.

② The litigation between the company and GSK’s subsidiary Tesaro regarding the Jemperli licensing agreement has not yet reached a final conclusion. Subsequent rulings may still affect future royalty revenue.